Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias

Background Vincristine sulfate liposome injection (VSLI; Marqibo®) is an encapsulated preparation of standard vincristine in sphingomyelin/cholesterol liposomes. Clinical trials in adults have demonstrated safety, tolerability, and activity, leading to Food and Drug Administration (FDA) approval for...

Full description

Saved in:

Bibliographic Details
Published in:	Pediatric blood & cancer Vol. 63; no. 6; pp. 997 - 1005
Main Authors:	Shah, Nirali N., Merchant, Melinda S., Cole, Diane E., Jayaprakash, Nalini, Bernstein, Donna, Delbrook, Cindy, Richards, Kelly, Widemann, Brigitte C., Wayne, Alan S.
Format:	Journal Article
Language:	English
Published:	United States Blackwell Publishing Ltd 01.06.2016 Wiley Subscription Services, Inc
Subjects:	acute lymphoblastic leukemia Adolescent Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - pharmacokinetics Chemotherapy Child Child, Preschool Female Hematology Humans Leukemia Liposomes Male Marqibo Maximum Tolerated Dose Neoplasms - drug therapy Oncology pediatric Pediatrics phase I Registries Vincristine - administration & dosage Vincristine - adverse effects Vincristine - pharmacokinetics Young Adult Marqibo phase I acute lymphoblastic leukemia pediatric
ISSN:	1545-5009, 1545-5017, 1545-5017
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!